Decoding the disease-associated proteins encoded in the human chromosome 4

Journal of Proteome Research

Volumn 12, Issue 1, 2013, Pages 33-44

  Chen, Lien Chin ^a   Liu, Mei Ying ^b   Hsiao, Yung Chin ^d   Choong, Wai Kok ^a   Wu, Hsin Yi ^c   Hsu, Wen Lian ^a,h   Liao, Pao Chi ^e   Sung, Ting Yi ^a   Tsai, Shih Feng ^b,f,g   Yu, Jau Song ^b   Chen, Yu Ju ^c,d  

^a INSTITUTE OF INFORMATION SCIENCE   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d INSTITUTE OF CHEMISTRY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^g NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^h CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Cancer biomarker; Chromosome 4; Chromosome centric human proteome project; MRM; SRM

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; ALPHA FETOPROTEIN; AMPHIREGULIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CASPASE 3; CASPASE 6; CYCLIN A2; FIBRINOGEN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; INITIATION FACTOR 4E; INTERLEUKIN 8; ISOPROTEIN; MEMBRANE PROTEIN; OSTEOPONTIN; PLATELET DERIVED GROWTH FACTOR C; PROTEIN; SERUM ALBUMIN; VASCULOTROPIN C;

ALCOHOL METABOLISM; ALCOHOLISM; AMINO ACID SEQUENCE; CANCER CELL; CANCER RESEARCH; CHROMOSOME 4; CHROMOSOME 4Q; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; GENE FREQUENCY; GENE FUNCTION; GENETIC DISORDER; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HETEROZYGOSITY LOSS; HUMAN; HUMAN CHROMOSOME; INDEL MUTATION; LIVER CARCINOGENESIS; MARKER GENE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEOMICS; PSEUDOGENE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; WOLFRAM SYNDROME;

CHROMOSOMES, HUMAN, PAIR 4; COMPUTATIONAL BIOLOGY; DATABASES, PROTEIN; DISEASE; GENOME, HUMAN; HUMAN GENOME PROJECT; HUMANS; PILOT PROJECTS; PROTEINS; PROTEOMICS;

EID: 84874102353     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr300829r     Document Type: Review

References (63)

1. Legrain, P.; Aebersold, R.; Archakov, A.; Bairoch, A.; Bala, K.; Beretta, L.; et al. The human proteome project: current state and future direction. Mol. Cell. Proteomics 2011, 10, M111 009993.
2. Paik, Y. K.; Jeong, S. K.; Omenn, G. S.; Uhlen, M.; Hanash, S.; Cho, S. Y.; et al. The Chromosome-Centric Human Proteome Project for cataloging proteins encoded in the genome. Nat. Biotechnol. 2012, 30, 221-223.
3. Ensembl genome browser. http://www.ensembl.org/Homo-sapiens/Location/ Chromosome?r=4%3A1-1000.
4. Lane, L.; Argoud-Puy, G.; Britan, A.; Cusin, I.; Duek, P. D.; Evalet, O.; et al. neXtProt: a knowledge platform for human proteins. Nucleic Acids Res. 2012, 40, D76-83.
5. Craig, R.; Cortens, J. P.; Beavis, R. C. Open source system for analyzing, validating, and storing protein identification data. J. Proteome Res. 2004, 3, 1234-1242.
6. Desiere, F.; Deutsch, E. W.; Nesvizhskii, A. I.; Mallick, P.; King, N. L.; Eng, J. K.; et al. Integration with the human genome of peptide sequences obtained by high-throughput mass spectrometry. Genome Biol. 2005, 6, R9.
7. Uhlen, M.; Bjorling, E.; Agaton, C.; Szigyarto, C. A.; Amini, B.; Andersen, E.; et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol. Cell. Proteomics 2005, 4, 1920-1932.
8. Yeh, S. H.; Chen, P. J.; Lai, M. Y.; Chen, D. S. Allelic loss on chromosomes 4q and 16q in hepatocellular carcinoma: association with elevated alpha-fetoprotein production. Gastroenterology 1996, 110, 184-192.
9. Yeh, S. H.; Lin, M. W.; Lu, S. F.; Wu, D. C.; Tsai, S. F.; Tsai, C. Y.; et al. Allelic loss of chromosome 4q21 approximately 23 associates with hepatitis B virus-related hepatocarcinogenesis and elevated alphafetoprotein. Hepatology 2004, 40, 847-854.
10. Goh, K. I.; Cusick, M. E.; Valle, D.; Childs, B.; Vidal, M.; Barabasi, A. L. The human disease network. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 8685-8690.
11. Zhou, L.; Liu, J.; Luo, F. Serum tumor markers for detection of hepatocellular carcinoma. World J. Gastroenterol. 2006, 12, 1175-1181.
12. Edenberg, H. J. The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants. Alcohol Res. Health 2007, 30, 5-13.
13. Walker, F. O. Huntington's disease. Lancet 2007, 369, 218-228.
14. Giasson, B. I.; Duda, J. E.; Murray, I. V.; Chen, Q.; Souza, J. M.; Hurtig, H. I.; et al. Oxidative damage linked to neurodegeneration byselective alpha-synuclein nitration in synucleinopathy lesions. Science 2000, 290, 985-989.
15. Horton, W. A.; Hood, O. J.; Machado, M. A.; Campbell, D. Growth plate cartilage studies in achondroplasia. Basic Life Sci. 1988, 48, 81-89.
16. Wellcome Trust Sanger Institute Cancer Genome Project, The Human Cancer Genome Project Home Page. http://www.sanger.ac. uk/genetics/CGP.
17. Genetic Association Database Home Page. http://geneticassociationdb.nih. gov/cgi-bin/index.cgi.
18. Becker, K. G.; Barnes, K. C.; Bright, T. J.; Wang, S. A. The genetic association database. Nat. Genet. 2004, 36, 431-432.
19. OMIM 164920. http://omim.org/entry/164920?search= kit&highlight= kit#reference17.
20. Rothschild, G.; Sottas, C. M.; Kissel, H.; Agosti, V.; Manova, K.; Hardy, M. P.; et al. A role for kit receptor signaling in Leydig cell steroidogenesis. Biol. Reprod. 2003, 69, 925-932.
21. Geissler, E. N.; Ryan, M. A.; Housman, D. E. The dominantwhite spotting (W) locus of the mouse encodes the c-kit protooncogene. Cell 1988, 55, 185-192.
22. Hirota, S.; Isozaki, K.; Moriyama, Y.; Hashimoto, K.; Nishida, T.; Ishiguro, S.; et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279, 577-580.
23. Joensuu, H.; Roberts, P. J.; Sarlomo-Rikala, M.; Andersson, L. C.; Tervahartiala, P.; Tuveson, D.; et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 2001, 344, 1052-1056.
24. Savage, D. G.; Antman, K. H. Imatinib mesylate a new oral targeted therapy. N. Engl. J. Med. 2002, 346, 683-693.
25. Holmes, M. V.; Shah, T.; Vickery, C.; Smeeth, L.; Hingorani, A. D.; Casas, J. P. Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies. PLoS One 2009, 4, e7960.
26. Yeh, S. H.; Chen, P. J.; Shau, W. Y.; Chen, Y. W.; Lee, P. H.; Chen, J. T.; et al. Chromosomal allelic imbalance evolving from liver cirrhosis to hepatocellular carcinoma. Gastroenterology 2001, 121, 699-709.
27. Marchio, A.; Meddeb, M.; Pineau, P.; Danglot, G.; Tiollais, P.; Bernheim, A.; et al. Recurrent chromosomal abnormalities in hepatocellular carcinoma detected by comparative genomic hybridization. Genes, Chromosomes Cancer 1997, 18, 59-65.
28. Shih, W. L.; Yu, M. W.; Chen, P. J.; Wu, T. W.; Lin, C. L.; Liu, C. J.; et al. Evidence for association with hepatocellular carcinoma at the PAPSS1 locus on chromosome 4q25 in a family-based study. Eur. J. Hum. Genet. 2009, 17, 1250-1259.
29. Yeh, S. H.; Wu, D. C.; Tsai, C. Y.; Kuo, T. J.; Yu, W. C.; Chang, Y. S.; et al. Genetic characterization of fas-associated phosphatase-1 as a putative tumor suppressor gene on chromosome 4q21.3 in hepatocellular carcinoma. Clin. Cancer Res. 2006, 12, 1097-1108.
30. Irizarry, K.; Kustanovich, V.; Li, C.; Brown, N.; Nelson, S.; Wong, W.; et al. Genome-wide analysis of single-nucleotide polymorphisms in human expressed sequences. Nat. Genet. 2000, 26, 233-236.
31. National Center for Biotechnology Information, Single Nucleotide Polymorphisms Database. http://www.ncbi.nlm.nih.gov/snp/.
32. Matsuo, Y.; Yokoyama, R.; Yokoyama, S. The genes for human alcohol dehydrogenases beta 1 and beta 2 differ by only one nucleotide. Eur. J. Biochem. 1989, 183, 317-320.
33. Hashibe, M.; Boffetta, P.; Zaridze, D.; Shangina, O.; Szeszenia-Dabrowska, N.; Mates, D.; et al. Evidence for an important role of alcohol-and aldehyde-metabolizing genes in cancers of the upper aerodigestive tract. Cancer Epidemiol., Biomarkers Prev. 2006, 15, 696-703.
34. Hashibe, M.; McKay, J. D.; Curado, M. P.; Oliveira, J. C.; Koifman, S.; Koifman, R.; et al. Multiple ADH genes are associated with upper aerodigestive cancers. Nat. Genet. 2008, 40, 707-709.
35. Uhlen, M.; Oksvold, P.; Algenas, C.; Hamsten, C.; Fagerberg, L.; Klevebring, D.; et al. Antibody-based protein profiling of the human chromosome 21. Mol. Cell. Proteomics 2012, 11, M111013458.
36. Su, J. S.; Tsai, T. F.; Chang, H. M.; Chao, K. M.; Su, T. S.; Tsai, S. F. Distant HNF1 site as a master control for the human class I alcohol dehydrogenase gene expression. J. Biol. Chem. 2006, 281, 19809-19821.
37. Christine, M.; Micheel, S. J. N.; Gilbert, S. O. Evolution of Translational Omics: Lessons Learned and Path Forward; Institute of Medicine of the National Academy of Sciences: Washington, D. C., 2012.
38. Ladunga, I. Large-scale predictions of secretory proteins from mammalian genomic and EST sequences. Curr. Opin. Biotechnol. 2000, 11, 13-18.
39. Bendtsen, J. D.; Nielsen, H.; von Heijne, G.; Brunak, S. Improved prediction of signal peptides: SignalP 3.0. J. Mol. Biol. 2004, 340, 783-795.
40. Nielsen, H.; Krogh, A. Prediction of signal peptides and signal anchors by a hidden Markov model. Proc. Int. Conf. Intell. Syst. Mol. Biol. 1998, 6, 122-130.
41. Bendtsen, J. D.; Jensen, L. J.; Blom, N.; Von Heijne, G.; Brunak, S. Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng., Des. Sel. 2004, 17, 349-356.
42. Moller, S.; Croning, M. D.; Apweiler, R. Evaluation of methods for the prediction of membrane spanning regions. Bioinformatics 2001, 17, 646-653.
43. Polanski, M.; Anderson, N. L. A list of candidate cancer biomarkers for targeted proteomics. Biomarker Insights 2007, 1, 1-48.
44. Anderson, N. L.; Anderson, N. G. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1, 845-867.
45. Wu, C. C.; Chien, K. Y.; Tsang, N. M.; Chang, K. P.; Hao, S. P.; Tsao, C. H.; et al. Cancer cell-secreted proteomes as a basis for searching potential tumor markers: nasopharyngeal carcinoma as a model. Proteomics 2005, 5, 3173-3182.
46. Xue, H.; Lu, B.; Lai, M. The cancer secretome: a reservoir of biomarkers. J. Transl. Med. 2008, 6, 52.
47. Pavlou, M. P.; Diamandis, E. P. The cancer cell secretome: a good source for discovering biomarkers? J. Proteomics 2010, 73, 1896-1906.
48. Makridakis, M.; Vlahou, A. Secretome proteomics for discovery of cancer biomarkers. J. Proteomics 2010, 73, 2291-2305.
49. Wu, C. C.; Hsu, C. W.; Chen, C. D.; Yu, C. J.; Chang, K. P.; Tai, D. I.; et al. Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas. Mol. Cell. Proteomics 2010, 9, 1100-1117.
50. Hu?ttenhain, R.; Soste, M.; Selevsek, N.; Rost, H.; Sethi, A.; Carapito, C. Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics. Sci. Transl. Med. 2012, 4, 142-194.
51. Prenzel, N.; Zwick, E.; Leserer, M.; Ullrich, A. Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: convergence point for signal integration and diversification. Breast Cancer Res. 2000, 2, 184-190.
52. Kufe, D. W. Mucins in cancer: function, prognosis and therapy. Nat. Rev. Cancer 2009, 9, 874-885.
53. Josic, D.; Clifton, J. G.; Kovac, S.; Hixson, D. C. Membrane proteins as diagnostic biomarkers and targets for new therapies. Curr. Opin. Mol. Ther. 2008, 10, 116-123.
54. Yildirim, M. A.; Goh, K. I.; Cusick, M. E.; Barabasi, A. L.; Vidal, M. Drug-target network. Nat. Biotechnol. 2007, 25, 1119-1126.
55. Bernsel, A.; Viklund, H.; Falk, J.; Lindahl, E.; von Heijne, G.; Elofsson, A. Prediction of membrane-protein topology from first principles. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 7177-7181.
56. Kall, L.; Krogh, A.; Sonnhammer, E. L. A combined transmembrane topology and signal peptide prediction method. J. Mol. Biol. 2004, 338, 1027-1036.
57. Krogh, A.; Larsson, B.; von Heijne, G.; Sonnhammer, E. L. Predicting transmembrane protein topology with a hidden Markovmodel: application to complete genomes. J. Mol. Biol. 2001, 305, 567-580.
58. Lo, A.; Chiu, H. S.; Sung, T. Y.; Lyu, P. C.; Hsu, W. L. Enhanced membrane protein topology prediction using a hierarchical classification method and a new scoring function. J. Proteome Res. 2008, 7, 487-496.
59. Reynolds, S. M.; Kall, L.; Riffle, M. E.; Bilmes, J. A.; Noble, W. S. Transmembrane topology and signal peptide prediction using dynamic bayesian networks. PLoS Comput. Biol. 2008, 4, e1000213.
60. Edwards-Jackson, N.; Kerr, S.; Tieu, H.; Ananworanich, J.; Hammer, S.; Ruxrungtham, K.; et al. Cardiovascular risk assessment in persons with HIV infection in the developing world: comparing three risk equations in a cohort of HIV-infected Thais. HIV Med. 2011, 12, 510-515.
61. Lai, J. S.; Cheng, C. W.; Sung, T. Y.; Hsu, W. L. Computational comparative study of tuberculosis proteomes using a model learned from signal peptide structures. PLoS One 2012, 7, e35018.
62. Liao, P. C.; Wang, A. H.; Chen, S. T. Taiwan proteomics society: an organization affiliated with HUPO. Mol. Cell. Proteomics 2008, 7, 1584-1585.
63. Paik, Y. K.; Omenn, G. S.; Uhlen, M.; Hanash, S.; Marko-Varga, G.; Aebersold, R.; et al. Standard guidelines for the chromosomecentric human proteome project. J. Proteome Res. 2012, 11, 2005-2013.